PHARMACEUTICAL BLEND INFUSION THEREOF AND PARKINSON'S DISEASE MONITORING SYSTEM

• US 20130274654A1
• Filed: 04/17/2013
• Published: 10/17/2013
• Est. Priority Date: 04/17/2012
• Status: Active Grant

• Current Assignee: Micrel Medical Devices S.A.
• Original Assignee: Micrel Medical Devices S.A.
• Inventors: Tsoukalis, Achilleas
• Granted Patent: US 10,335,540 B2
• Time in Patent Office: Days
• US Class Current: 604/67
• CPC Class Codes: A61M 2205/3569 sublocal, e.g. between console and disposable
• CPC Class Codes: A61M 2205/502 User interfaces, e.g. screens or keyboards
• CPC Class Codes: A61M 2205/58 Means for facilitating use, e.g. by people with impaired vision
• CPC Class Codes: A61M 2205/60 with identification means
• CPC Class Codes: A61M 5/142 Pressure infusion, e.g. using pumps
• CPC Class Codes: A61M 5/172 electrical or electronic A61M5/16804, A61M5/16831 take precedence
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: G16H 20/17 delivered via infusion or injection

Abstract

The invention relates to a system for administring drug to a Parkinson'"'"'s disease patient comprising (a) a drug; (b) a storing bag for the drug; (e) a pump for administering the drug; (d) a pump controller for controlling the pump activity, the pump controller having access to a correlation of a first parameter t_x and a second parameter A_t, and to the current first parameter t_x, wherein the first parameter t_x is correlated with a certain activity of the patient and the second parameter A_t is correlated with a dosage of the drug and the pump controller controls the pump activity In dependence of the first parameter t_x and the correlation, and/or wherein the system comprises (e) a storing hag the drug suitable for pre-filling and long-term oxidations-free storage having a multi layer wall with the internal layer made of EVA or cyclic, polyolefines and at least one further layer made of EVOH.

Claims

1. System for administering a drug to a Parkinson'"'"'s disease patient comprising (a) a drug, (b) a storing bag for the drug, (c) a pump for administering the drug, and (d) a pump controller for controlling the pump activity,

the pump controller having access to a correlation of a first parameter t_x and a second parameter A_t, and to the current first parameter t_x,

wherein the first parameter t_x is correlated with a certain activity of the patient and the second parameter A_t is correlated with a dosage of the drug and the pump controller controls the pump activity in dependence of the first parameter t_x and the correlation,

and/or wherein the system composes (e) a storing bag the drug suitable for pre-filling and long-term oxidations-free storage having a mufti layer wall with the internal layer made of EVA or cyclic polyolefines and at least one further layer made of EVOH.

2. System according to claim 1, wherein the storing bag for the drug comprises internal micro-striation texture.

3. System according to claim 1, wherein the system comprises (f) means for therapy feedback measurement and report and/or (g) recording and monitoring infusion and feedback means, and/or (h) remote therapy regiment adjustment means.

4. System according to claim 1, wherein the controller further has access to a parameter “

a”

for a master volume control, wherein the controller controls the pump activity by a multiplication of the parameter a with the second parameter A_t that is correlated with the first parameter t.

5. System according to claim 1, wherein the controller further has access to a parameter “

b”

, wherein the controller controls the pump activity in case of a change of the first parameter by a multiplication of parameter b with the difference between the second parameter A_t+z, that is correlated with the first parameter t+z after the change and the second parameter A_tx that is correlated with the first parameter t_x before the change to amend the dosage z minutes prior to the change by adding the result of the multiplication (b*(A_t+z-A_tx) to the dosage according to A_tx.

6. System according to claim 1, wherein the system is arranged in a way that the first parameter t_x can be amended by the patient while parameters a, b and A_t can be amended by the attending physician and/or a by a control system that is in contact with the system.

7. System according to claim 1, wherein the system further comprises an interface for submitting data to a remote control system and/or a remote data storage unit and/or the attending physician and/or wherein the system further comprises an interface for receiving data from a remote control system and/or a remote data storage unit and/or the attending physician.

8. System according to claim 1, wherein the system further comprises means for measurement of the status of the patient.

9. System according to claim 8, wherein the means for measurement of the status of the patient are selected from the group 3D accelerometer, gyroscope, electromyogram, and bed foil with sensing of movement, heart rate and/or respiration during sleep capability.

10. System according to claim 1, wherein the system comprises a patient'"'"'s feedback function which comprises an input interlace for a response of the patient to questions asked by the patient'"'"'s feedback function.

11. System according to claim 1, comprising means for detecting malfunction of the system.

12. System according to claim 9, having means for sensor movement measurement which is done in vicinity of a proximity sensor activation when two wrists come close together or a button is pressed on a wrist band.

13. System according to claim 1, wherein the system is arranged in a way that in case of negative feedback by the patient, critical status of the patient and/or malfunction of the system the respective information is automatically submitted to a remote control system and/or a remote data storage unit and/or the attending physician.

14. System according to claim 1, wherein the drug comprises Levodopa and/or Carbidopa and/or benserazide preferably in the form of microscopic particles, suspended in a viscous liquid having a viscosity of 300±

80 mPa·

s measured at a moderate shear rate.

15. System according to claim 1, wherein the drug is apomorphine.